Drug intelligence / Profile preview

lidocaine + vasopressin

Development stage: Unknown
Modality: Small Molecules
Administration: Local Injection

Overview

A combination of lidocaine and vasopressin used primarily for local anesthesia. Lidocaine acts as a local anesthetic by blocking sodium channels in nerve membranes, preventing the initiation and conduction of nerve impulses. Vasopressin causes vasoconstriction, which reduces local blood flow at the injection site. This reduction in blood flow decreases the rate at which lidocaine is removed from the area, promoting localization and retention of lidocaine in target tissues and extending the duration of anesthesia without significantly affecting overall circulatory dynamics.

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)AVPR2 (Arginine vasopressin V2 receptor)AVPR1B (Vasopressin V1b Receptor)AVPR1A (Arginine vasopressin receptor 1A)

Beyond the preview

Go deeper on lidocaine + vasopressin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine + vasopressin.

Explore the full profile